Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Biocatalytic Asymmetric Reduction. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel biocatalytic route for chiral alcohol intermediates ensures >99% ee and scalable production for beta-3 agonists.